摘要
目的:观察恩替卡韦联合甘草酸二铵对慢性乙型病毒性肝炎患者肝纤维化及肝功能的影响。方法:选择2017年8月-2019年7月于本院治疗的84例慢性乙型病毒性肝炎患者。按随机数字表法分为观察组和对照组,每组42例。对照组接受恩替卡韦治疗,观察组于对照组基础上加用甘草酸二铵治疗。比较两组肝纤维化指标[层黏连蛋白(LN)、透明质酸(HA)、Ⅲ型前胶原(PCⅢ)]、肝功能指标[谷草转氨酶(AST)、谷丙转氨酶(ALT)]、HBV-DNA转阴率及不良反应发生情况。结果:治疗前,两组LN、HA、PCⅢ、AST、ALT水平比较,差异均无统计学意义(P>0.05)。治疗6个月后,两组LN、HA、PCⅢ、AST、ALT水平均降低,且观察组上述指标水平均低于对照组,差异均有统计学意义(P<0.05)。观察组HBV-DNA转阴率为85.71%,高于对照组的64.29%,差异有统计学意义(P<0.05)。观察组不良反应发生率为14.29%,与对照组的11.90%比较,差异无统计学意义(P>0.05)。结论:恩替卡韦联合甘草酸二铵治疗慢性乙型病毒性肝炎可有效改善患者肝功能,逆转肝纤维化,有利于提高HBV-DNA转阴率,且不会增加不良反应。
Objective:To observe the effect of Entecavir combined with Diammonium Glycyrrhizinate on liver fibrosis and liver function in patients with chronic viral hepatitis B.Method:Eighty-four patients with chronic viral hepatitis B who treated in our hospital from August 2017 to July 2019 were selected.According to the random number table method,the patients were divided into observation group and control group,42 cases in each group.The control group received Entecavir,the observation group was treated with Diammonium Glycyrrhizinate on the basis of the control group.Liver fibrosis indexes[laminin(LN),hyaluronic acid(HA),procollagenⅢ(PCⅢ),liver function indexes[aspartate aminotransferase(AST),alanine aminotransferase(ALT)],HBV-DNA negative conversion rate and adverse reactions were compared between two groups.Result:Before treatment,there were no significant differences in the levels of LN,HA,PCⅢ,AST and ALT between two groups(P>0.05).At 6 months after treatment,the levels of LN,HA,PCⅢ,AST and ALT in two groups were decreased,and the above indexes in the observation group were lower than those in control group,differences were statistically significant(P<0.05).The negative rate of HBV-DNA in the observation group was 85.71%,which was higher than 64.29%in the control group,the difference was statistically significant(P<0.05).The incidence of adverse reactions in the observation group was 14.29%,compared with 11.90%in the control group,the difference was not statistically significant(P>0.05).Conclusion:Entecavir combined with Diammonium Glycyrrhizinate in the treatment of chronic viral hepatitis B can effectively improve liver function,reverse liver fibrosis,improve the negative rate of HBV-DNA,and will not increase adverse reactions.
作者
张嵩
李钦
徐文君
熊英
ZHANG Song;LI Qin;XU Wenjun;XIONG Ying(People’s Hospital of Shangrao City,Shangrao 334000,China;不详)
出处
《中国医学创新》
CAS
2020年第24期131-134,共4页
Medical Innovation of China
关键词
慢性乙型病毒性肝炎
恩替卡韦
甘草酸二铵
肝纤维化
肝功能
Chronic viral hepatitis B
Entecavir
Diammonium Glycyrrhizinate
Liver fibrosis
Liver function
